肥胖和心力衰竭与保存的喷射分数
Tetyana M Ternushchak1, Marianna I Tovt-Korshynska1, Oksana M Moskal1
1UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE.
Wiadomosci lekarskie (Warsaw, Poland : 1960)
|May 1, 2024
概括
心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭中心脏衰竭 这些患者表现出更高的炎症标志物和脂质概况,尽管NT-proBNP水平较低.
科学领域:
- 心脏病学 心脏病学
- 肥胖医学 肥胖医学
- 心血管研究研究心血管研究
背景情况:
- 保存喷射分数 (HFpEF) 的心力衰竭是一个日益增长的临床挑战.
- 中心肥胖症越来越被认为是影响心血管健康的重要并发症.
- 了解中心肥胖对HFpEF的特定影响对于风险分层和管理至关重要.
研究的目的:
- 综合评估中心肥胖症HFpEF患者的临床和心声学特征.
- 为了将这些特征与没有肥胖的HFpEF患者和健康的对照进行比较.
- 在HFpEF人群中确定与中心肥胖相关的特定心血管风险.
主要方法:
- 招募了73名中心肥胖的HFpEF患者和70名没有肥胖的HFpEF患者,以及69名年龄相匹配的健康对照.
- 进行身体检查并收集有关空腹葡萄糖,胰岛素,脂质样本,炎症标志物 (hs CRP),NT-proBNP和功能的数据.
- 进行标准的胸腔横心回声学 (2D和多普勒) 以评估心脏结构和功能,包括左心室和右心室参数.
主要成果:
- 肥胖的HFpEF患者与非肥胖的HFpEF患者相比,表现出明显更高的透析血压,葡萄糖,脂质样本,尿酸和hsCRP.
- 尽管HF症状更严重,但肥胖的HFpEF患者的NT-proBNP水平较低.
- 心声检查显示,肥胖HFpEF患者的肥胖相关的左心室扩张功能障碍更明显,LV尺寸和质量增加,右心室扩张和功能障碍更大.
结论:
- 患有HFpEF的肥胖患者存在心血管风险因素的升高,包括更高的透析血压,动脉动脉脂症和胰岛素耐药性.
- 这些患者表现出系统性炎症增加和心声学证据显著的左心室和右心室扩张功能障碍.
- 在HFpEF中,中心肥胖预示着未来心血管事件的风险更高,需要有针对性的干预措施.
相关概念视频
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:22Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
01:26Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
01:22Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
01:26Heart Failure Drugs: Inotropic Agents
574
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
574